Abstract-Rapid induction and maintenance of blood flow through new vascular networks is essential for successfully treating ischemic tissues and maintaining function of engineered neo-organs. We have previously shown that human endothelial progenitor cells (EPCs) form functioning vessels in mice, but these are limited in number and persistence; and also that human adipose stromal cells (ASCs) are multipotent cells with pericytic properties which can stabilize vascular assembly in vitro.
A ssembly of new vascular networks for therapeutic purposes has been critical but elusive for tissue engineering and angiogenesis. A general requirement for preserving viability within a regenerating region is that a vascular bed is assembled or expanded sufficiently to ensure adequate tissue perfusion. Also important to success of such applications is the ability of any network to anastomose or inosculate promptly with the vessels of immediately adjacent tissues. Cell-based revascularization therapies were tested in patients with various ischemic diseases. These studies used progenitor cells from bone marrow 1,2 and skeletal muscle 3, 4 to treat patients with myocardial infarction, 1,2 heart failure, [3] [4] [5] [6] and peripheral vascular disease. 7, 8 Despite accumulating data and recent metaanalyses 9, 10 that support the hypothesis that progenitor cells have high potential for promoting tissue revascularization and functional recovery, invasive methods of cells harvest and their low abundance may limit adoption some of progenitor cells for therapies. Recent approaches were focused on evaluating cells derived from more available tissues including adipose tissue 11, 12 and umbilical cord blood. 13, 14 Endothelial progenitor cells (EPCs) isolated from adult peripheral blood, 15 bone marrow, umbilical cord blood, 13 and vessel wall 16 were intensively studied over the past decade. Recently, we have shown that umbilical cord blood contains a population of EPCs with particularly high proliferative potential, which we have termed endothelial colony forming cell. 13 Implantation of endothelial colony forming cells in a matrix in mice resulted in in vivo functional vessels formation. 17 Although the presence of blood cells within capillary networks formed by such human EPCs confirmed anastomoses with host vasculature, the neovessels were limited in frequency and size. This extended a prior observation for implants containing untransformed adult endothelial cells (ECs), which yielded vessels characterized as narrow-caliber with single-layer walls. 18 With nontransformed ECs, failure to establish stable, mature vasculature may be attributable to prolonged absence of a stabilizing layer of mural cells such as pericytes or smooth muscle cells (SMCs). Although EPCs secrete multiple angiogenic factors, conditions within the gel matrix may not attract sufficient host mural cells within an appropriate time frame to promote stability of neovasculature before competing forces act to disassemble the vessels. Although coimplantation of pericytes with EPCs might promote stabilization and maturation of the vessels, an adequate and easily-accessible source of pericytes has not been previously recognized. However, network stabilization by mural cells has been shown by the coimplantation of ECs with human saphenous vein-derived SMCs 19 and murine C3H-10T1/2 cells. 20 Unfortunately, obtaining the former requires excision of a vein, whereas the latter is not appropriate for therapies.
We have recently discovered that adipose stromal cells (ASCs), a population of pluripotent mesenchymal cells that are readily available in large numbers from adipose tissue, are predominantly associated with vessels in vivo, and phenotypically and functionally equivalent to pericytes associated with microvessels. 21 Recognition of this ASC function provides a new context for understanding the observations that local or systemic ASC delivery restores blood flow in ischemic muscle tissues, [22] [23] [24] an activity that has been proposed to occur via several mechanisms, including paracrine support 24, 25 of ECs with suppression of their apoptosis 22, 23 and ASC integration into host vasculature. 23 Our previous finding that ASC possess properties of pericytes and are able to stabilize endothelial networks in vitro 21 suggested the possibility that provision of ASCs along with ECs in vivo might promote and stabilize new vessel formation, thus potentially providing an approach to enhance development of vascular networks.
Materials and Methods
An expanded version of Materials and Methods section is available in online data supplement at http://circres.ahajournals.org and includes detailed methods for the following: isolation and cultivation of EPCs from umbilical cord blood and ASCs, formation and implantation of collagen/fibronectin gels containing embedded cells, fabrication of artificial tissues carrying adipocytes and islets, implantation of cells into mouse ears, isolation of porcine islets, evaluation of vascular endothelial growth factor (VEGF) accumulation in ASC-conditioned media, immunohistochemical evaluation of cellular implants and mouse ear tissue, proliferation and apoptosis assays, and statistical analysis.
Results

Vasculogenesis by Human Primary ASCs and EPCs
We previously showed in vitro that cocultures of ASCs and ECs on Matrigel in a ratio of 1:3 to 1:7 ASC:EC produced a stable vascular network with inner layers formed by ECs and outer layers formed by ASCs. 21 Based on this observation, in vivo experiments in the present study were conducted with a ratio of 1:4 (ASC:EPC).
To evaluate the potential for ASCs to assist in vessel formation by ECs and stabilization of neovasculature, we conducted studies with collagen/fibronectin matrix containing: (1) EPCs, (2) ASCs, or (3) a 1:4 mixture of ASCs to EPCs. A clear difference was found in the appearance of the implants harvested from mice at 2 weeks after implantation (Figure 1a through 1c) . Whereas implants containing EPCs or ASCs alone were whitish in color with superficial, thin vascular structures, matrices containing the combination of the 2 cell types were consistently red because of the presence of blood-filled vessels. Additionally, it was observed that implants containing both cell types were tightly associated with the muscle fascia, whereas implants with either ASCs or EPCs were loosely attached to host tissue.
The visible differences in blood content of implants with human ASCs and EPCs indicated that this combination formed an extensive network of vessels that connected with the host vasculature. Microscopic examination of implant sections stained with hematoxylin/eosin (Figure 1d through 1f) was used 
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to identify vessels as luminal structures that were further classified according to their size, presence of single or multiple layers of cells in the vascular wall, and the presence or absence of contained blood elements. Analysis of implants combine from all independent studies revealed that among implants containing only EPCs: 20% had at least 1 multilayered vessel, 40% had only single-layer vessels, and the remaining 40% had no vessels. Among implants containing only ASCs, none of the implants contained complex multilayered vessels, 30% contained small simple vessels, and 70% possessed no visible vessels. Remarkably, all implants containing both cell types contained numerous vessels comprised of an endothelial layer surrounded by a layer of mural cells, with connections to the host vasculature evidenced by the presence of erythrocytes within the lumens (Figure 1f ). Vessel density in the implants was further assessed by staining section for human ECs (CD31/PECAM) and smooth muscle cells (Figure 2g and 2h) . EPC-containing implants gave rise to 26.6Ϯ5.8 CD31 ϩ and 13.1Ϯ3.6 ␣-SMA ϩ vessels per millimeter squared, the latter indicating that host mural cells invaded the implants and contributed to vessel formation. ASC implants possessed 10.2Ϯ3.5 ␣-SMA ϩ vessels per millimeter squared, which were presumably derived from the input human ASCs. Vessels containing human CD31-expressing cells were not detected in any of the implants containing only ASCs, indicating that the observed vessels either incorporated host ECs or were pseudovessels formed by ASCs but lacking an endothelial layer. By comparison to these groups, Mix implants contained remarkably more vessels as enumerated by both CD31 (122.4Ϯ9.8 vessels per millimeter squared) and ␣-SMA (124.7Ϯ19.7 vessels per millimeter squared) staining (PϽ0.001). The observed similarity in density of CD31 ϩ and ␣-SMA ϩ vessels detected in implants formed by the ASC-EPC combination led to hypothesis of routine joint participation of both cell types in the neovessel formation. Analysis of the vascular networks with respect to vessel diameter revealed that the dual cell implants gave rise to a broader distribution of vascular dimension, To confirm that mixed implants formed multilayered vessels, sections were double-stained with antibodies directed against the endothelial marker CD31 and against the ASC/mural cell marker ␣-SMA. Analysis of sections by confocal immunofluorescence technique (Figure 3a through 3d) confirmed the presence of bilaminar vessels with an inner layer formed by donor human EPCs surrounded by an outer layer of ␣-SMA ϩ cells (presumably ASCs). Moreover, the presence of autofluorescent erythrocytes (green) in the lumen was apparent.
To test the origin of the mural layer of the newly formed vessels, experiments were conducted in which ASCs transduced with lentiviral vectors encoding green fluorescent protein (GFP) were coembedded with EPCs and implanted into mice. Immunodetection of GFP at day 14 revealed that vessels were routinely coated by GFP-expressing ASCs (Figure 3e and 3f), confirming human donor origin of the mural cells of the assembled vessels. Also, analysis of the sections probed for GFP and ␣-SMA antigens confirmed that the majority of ASCs in implants robustly expressed ␣-SMA (Figure 3g through 3j) . 
Donor-Derived Neovascular Networks Link to Host Vasculature
It is apparent from the above data that ASCs and EPCs in the matrix operate in concert to assemble a vascular network with a range of diameters in these implants. To determine the degree to which these vessels inosculated with the host vasculature, the CD31-positive vessels that clearly contained erythrocytes were scored at 14 days postimplantation (Figure 4a ). In the implants containing solely EPCs, 3% of the total vessels detected contained erythrocytes, whereas none was observed in ASC implants. Conversely, nearly 75% (92.5Ϯ16.2 per millimeter squared) of CD31 ϩ vessels observed in Mix implants were functional and blood-filled, demonstrating connections with host (mouse) vasculature and incorporation into the circulatory system. To support our hypothesis that the neovessels were functional, implants were imaged by ultrasound following IV injection of microbubbles into host mice. These dynamic images revealed multiple functional vessels traversing the implant region (see Online Movie). To determine whether the cord blood source of EPC was critical for the vascular assembly process and inosculation with the host vasculature, implants containing ASC in combination with ECs either derived from human umbilical vein (HUVEC), human placenta (Pl-EC), or adult human adipose tissue (AT-EC), were evaluated. The density of CD31 ϩ vessels containing erythrocytes in implants containing ASCϩHUVEC, ASCϩPl-EC, or ASCϩAT-EC was 33.3Ϯ12.6, 31.5Ϯ9.0, and 61.1Ϯ1.0 vessels per millimeter squared, respectively (Online Figure II) , confirming that ECs from several sources were able to partner with ASCs in vascular network assembly. The dynamics of vessel formation by the combination of cells in vivo were evaluated in implants harvested at 2, 4, and 6 days after placement. At day 2 following implantation, ECs had assembled into tubes, which had not formed apparent connections with host vasculature (Figure 4b and 4e). By day 4, a significant number of newly formed vessels (100.1Ϯ8.1 per millimeter squared) were filled with erythrocytes (Figure 4c and 4e) followed by an additional increase by 45% by day 6 (147.5Ϯ22.1 per millimeter squared; Figure 4d and 4e). Moreover, the vessels had formed branching networks throughout the implants (Figure 4d ). Thus, the cooperative formation of vessels by ASCs and EPCs occurs quickly in vivo and is followed by connection with the host vasculature.
Cooperative Vasculogenesis by ASCs and EPCs Is Associated With Cell Proliferation and ASC-Mediated Reduction of EPC Apoptosis
5-Bromodeoxyuridine (BrdUrd) labeling was used to determine the cycling status of cells comprising vessels within the matrices containing both cell types. Probing sections against BrdUrd revealed that a significant number of cells underwent DNA synthesis during the first 6 days following matrix insertion and were identified throughout the implants, with numerous BrdUrd-positive cells located in vessel walls (Figure 5a ) in both the luminal (EPCs) and abluminal layer (ASCs). To further confirm the identity and location of cycling cells, sections were simultaneously probed for Ki67 and either CD31 or ␣-SMA antigens. As shown in Figure 5e and 5i, Ki67 expression colocalized with both human CD31-positive luminal cells (EPCs) and ␣-SMA-positive ASCs contributing to the vascular mural layer. Because we previously observed that implants containing solely EPCs formed transient vessels, we next determined whether ASCs served to prevent vessel regression by affecting apoptosis of ECs. Matrices containing ASCs and EPCs alone or both were analyzed for apoptotic cells by TUNEL staining at day 14 postimplantation (Online Figure III, b) . Many apoptotic cells were observed in matrices implanted with only EPCs. Conversely, implants with only ASCs had few apoptotic cells and importantly, apoptosis was suppressed to very low levels in combination implants.
Crucial Role for Platelet-Derived Growth Factor in Cooperative Vessel Assembly by ASCs and EPCs
We previously described in vitro interaction of ASCs and ECs, accompanied by secretion of complementary growth factors, including platelet-derived growth factor (PDGF)-BB by ECs and VEGF by ASCs. 21 To determine whether the in vivo process of vasculogenesis conducted by the combined cells depended on signaling by PDGF-BB, gels were implanted with the addition of either control or anti-PDGF-BB neutralizing antibodies. Staining the sections for CD31 (Figure 6a and 6b ) and ␣-SMA (Figure 6c and 6d) revealed the specific disruption of vascular assembly by antagonism of PDGF-BB, whereas both ASCs and ECs survive within these gels to the same extend based on the TUNEL staining (Online Figure IV) , their assembly into lumen-containing structures is notably absent in the presence of anti-PDGF-BB antibodies.
To evaluate for bidirectional signaling between EPCs and ASCs, we determined the effect of PDGF-BB, a factor secreted by EPCs, on ASC secretion of VEGF, in turn a key factor for EPCs physiology. PDGF-BB exposure upregulated ASC secretion of VEGF by 2.4-fold (Figure 6e ). At the same time, EPC-conditioned media upregulated VEGF secretion by ASCs by more than 9-fold in comparison with control media (EBM-2/5% FBS), whereas preincubation of EPC-conditioned media with PDGF-BB neutralizing IgGs partially (Ϸ50%) suppressed this effect (Figure 6f ). Neither EBM-2/5% FBS nor EPC-conditioned media revealed any signal for hVEGF protein.
Vasculogenesis by ASCs and EPCs Without Exogenous Matrix
To test the ability of directly injected ASCs and EPCs to establish vasculogenesis in host tissue, and the necessity of exogenous collagen/fibronectin matrix for this process, we injected distal ear pinnae of mice with the cell mixture after suspension in either collagen/fibronectin gel (nϭ4) or media (nϭ4). Fourteen days postdelivery, immunohistochemical analysis of ear sections revealed human CD31-positive, functional (RBC-filled) vessels in both treatment groups (Figure 7a and 7b) .
Collagen Implants Carrying Adipocytes and Islets
To evaluate the potential of ASCs and EPCs to establish a functional vascular network in the context of an admixed parenchymal or secretory cell population, collagen/fibronectin gels were fabricated carrying ASCs and EPCs in a 1:4 ratio, combined with either freshly isolated mature human adipocytes or pig pancreatic islets. Immunohistochemical analysis of these constructs harvested after 2 weeks revealed that implants carrying adipocytes had typical morphology of vascularized adipose tissue (Figure 8a and 8b) , whereas implants carrying islets contained vascular networks with clusters of cells staining positive for insulin (Figure 8d  through 8f) . Quantitation of vessels in implants containing adipocytes revealed a density of 86.2Ϯ2.9 vessels per milli- meter squared, and in implants with islets, a density of 38.6Ϯ2.9 vessels per millimeter squared.
Discussion
Engineering of tissue constructs with thickness greater than accommodated by gas or nutrient diffusion will require practical means for provision of vascular components that invest constructs and provide blood flow promptly at implantation. Additionally, local augmentation of vascular network development has been a goal for therapy of disorders such as myocardial infarction and peripheral vascular diseases. This study demonstrates for the first time the ability of 2 readily available, genetically unmodified primary human cell types, ASCs and ECs isolated from umbilical cord blood and from umbilical vein, placenta, and adult adipose tissue, to synergize in de novo formation of vascular networks in implanted collagen matrices, as well as in the context of admixed parenchymal nonvascular cells. Important to potential utility of this approach is the fact that ASCs and EPCs represent cells that can be obtained from humans with minimal difficulty and can be rapidly amplified after initial isolation if required. 13, 26 Previous studies demonstrated that human adult or umbilical cord blood-derived ECs alone after embedding into the matrices developed low-caliber vessel networks with limited persistence. However, their coimplantation with adult human SMCs 27 or C3H10T1/2 cells bearing characteristics of SMCs 20 resulted in vascular networks composed of vessels with greater caliber and thicker walls. Our recent finding that ASCs are expressing markers (CD140a, CD140b, NG2) and physiological characteristics of pericytes 21 prompted in vivo evaluation of ASC and EC interaction. The present study confirmed previous observations that implants comprised only of EPCs demonstrate limited vascular network formation. At the same time, combination of EC-ASC in implants led to development remarkably dense and stable vascular network, which supported the main hypothesis of our study that ASC are able to behave as pericytes in vivo. An important effect of ASCs on ECs clearly involves abrogation of marked apoptosis present in implants containing only ECs. This is also consistent with our prior findings that factors released from ASCs can protect ECs from apoptosis, 24 as well as stabilize EC cord formation on Matrigel in vitro settings. 21 Several molecular mechanisms may be involved in these effects of ASCs on ECs, including the secretion by ASCs of diffusible proangiogenic and antiapoptotic factors (such as VEGF and angiopoietin-1) and direct contact with forming endothelial tubes.
Given this role of ASCs in supporting ECs survival during the process of vasculogenesis, we explored whether ECs play a complementary role in modulating ASCs behavior via factors secreted by ECs. PDGF-BB is a key factor secreted by ECs 28 and EPCs (data not shown), for which we have previously demonstrated functional receptors on ASCs and their proliferative response. 21 Interruption of vascular assembly by local blockade of PDGF-BB signaling (with neutralizing antibodies) suggested a crucial role for this factor in signaling from EPCs to ASCs during vasculogenesis ( Figure  6 ). We thus hypothesized that blockade of PDGF-BB signaling prevented formation of mature vessels by reducing ASCs migration toward EPCs involved in lumen formation, with consequent diminution of ASC support for EPC, because of either loss of proximity or alteration of the ASCs secretory profile. This concept is supported by our finding that PDGF-BB secreted by EPCs plays a dominant but not solitary role in the stimulation of VEGF secretion by ASC ( Figure 6 ); this in turn is important for EC survival 29 and proliferation. This is also consistent with previous findings that exposure of human tenocytes, C3H10T1/2, or human myometrial SMCs to PDGF-BB increases VEGF expression. 29 -31 Both in the context of an engineered implant and therapeutic augmentation of tissue perfusion, timely provision of functional circulation is essential. Accordingly, it is notable that the implanted cells organized into vessels and established communication with the host circulation by day 4 following implantation in the dual cell system (Figure 4 ). Analysis of cell cycle revealed active proliferation of the cells in both vascular layers in the implants, suggesting involvement of proliferation in neovessels remodeling ( Figure 5) . The extent to which input cells are initially capable of expansion following implantation is not clear, but stabilization of the vascular density between days 7 and 14 postimplant in the collagen gels, suggests mechanisms controlling proliferation, concurrently with vascular remodeling in the context of flow.
One potential application of this approach is in fabrication of soft tissue or neoorgans, such as adipose implants for reconstructive surgery, as well as for metabolic or secretory tissues such as liver and pancreas. Although the sufficiency and persistence of the vascular network provided by ASCs and EPCs requires further evaluation, the present experiments (Figure 8 ) provide an initial demonstration that coimplantation of the cell mixture together with adipocytes or islets can establish neoorgans populated by such parenchymal cells.
The "2-cell system" also provides a means for evaluating the role of matrix in vasculogenesis. Although the collagen/ fibronectin matrix was used in most experiments to provide a supportive scaffold, we speculate that cell delivery in a range of matrices may assist both in restricting cells redistribution and augmenting their survival, particularly in ischemic environments, which may be hostile to implanted cells. In addition to delivery within exogenous matrix, results of cell injection into mouse pinnae (Figure 7) show that the mixture of cells is capable of assembly into vascular structures without exogenous extracellular matrix proteins.
The ready availability of ASCs and EPCs from clinically feasible sources, and their simple, well-defined preparation provide attractive features compare with previous approaches. Although use of human SMCs, primarily from dermis, 18, 32 has been described experimentally, the need for significant expansion because of the limited cell number practically available distinguishes this type of mural cell from ASCs.
Another approach to vascularization of tissue-engineered constructs is suggested by observations that both ASCs and ECs are present within enzymatically dissociated adipose tissue, [22] [23] [24] although in variable proportions depending on the preparation used. [33] [34] [35] It has been shown previously and is consistent with the observations of our study (Online Figure  III) that these heterogeneous adipose-derived cell mixtures are able to establish functional vasculature when transplanted to in vivo models. 36, 37 Although these systems are attractive in the use of solely adipose tissue as the source of vascular components, 37, 38 their utility may be hampered by the variability in viability and composition of the product of tissue harvesting and digestion without additional cell characterization. In addition, it has recently been demonstrated that mature ECs possess decreased ability to partner with mural cells to establish functional vasculature than cord bloodderived cells. 19, 20 A potential limitation of the clinical application of the approach described in this study is the use of allogeneic EPCs, which may require HLA host/donor matching for implants engineering or tissue revascularization. Our prior description of cord blood as a rich source of high proliferative EPCs 13, 39 suggests that extensive EPC expansion and banking may provide adequate source of cells as a component of vasculogenic therapeutic mixture for proposed applications. It is intriguing that ASCs were characterized as possessing immunosuppressive properties 40 ; we speculate that factors secreted by ASCs could alter immune response caused by heterologous ECs.
We conclude that the EC-ASC combination provides a clinically practical approach for engineering constructs composed of stable vascular networks and functional parenchymal cellular components that could be used for secretion of endogenous or specifically overexpressed bioactive factors and for augmentation of perfusion of ischemic tissues.
Sources of Funding
Supported by NIH grant R01 HL77688-01 and VA Merit Review grants (to K.L.M.); NIH grant T32 HL0799905 and American Heart Association Postdoctoral Award 0727777Z (to D.T.); and the Cryptic Masons' Medical Research Foundation.
Disclosures
Dmitry Traktuev, Brian Johnstone, and Keith March disclose an ownership interest in intellectual property related to findings covered within this manuscript.
1
Supplement Material Expanded Materials and Methods
All procedures for collecting human umbilical cord and adipose tissues were approved by the Indiana University School of Medicine Institutional Review Board.
UCB EPC isolation
Blood was collected from umbilical cord veins of healthy newborns (38-40 weeks gestational age) as previously described 1 Cells were passaged after becoming 90-100% confluent and used at passage 4-6.
Isolation and culture of human adipose stromal cells (hASCs)
Human subcutaneous adipose tissue samples obtained by liposuction were agitated in 1 mg/ml Collagenase Type I (Worthington Biochemical, Lakewood, NJ) prepared in DMEM/F12 medium (Invitrogen), supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin, for 2 hours at 37° C followed by centrifugation at 300g for 8 minutes to separate the stromal cell fraction (pellet) from adipocytes. The pellet was resuspended in DMEM/F12 medium supplemented with 10% FBS filtered through 250
μm Nitex (Sefar America Inc., Kansas City, MO) and centrifuged at 300g for 8 minutes.
To eliminate erythrocytes the pellet was treated with RBC lysis buffer (154 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 10 minutes. The final pellet was resuspended and cultured in EGM-2MV media (Cambrex). ASC monolayers were passaged when 60-80% confluent and used at passage 3-6.
Formation and implantation of collagen/fibronectin gels containing embedded cells
Gel implants were cast as previously described with minor modifications 2 . Prior to In the set of experiments addressing the role of PDGF-BB in EPC-ASC vessel assembly, 10 ng/ml of neutralizing anti-human PDGF-BB IgGs or isotype control goat IgG (RnD Systems) were added to the cell/gel mixture prior to polymerization.
Implantation of cells into mouse ear
Cord blood EPCs and ASCs mixed at a ratio of 4:1 (EPCs:ASCs) were suspended in either rat tail collagen/fibronectin gel (as above) or in EGM-2/10%FBS medium at a concentration of 2x10 6 cells/ml, and 50 ul of each suspension were directly injected into the pinnae of NOD/SCID mouse ears. Fourteen days post-injection, mice were sacrificed with gas inhalation (CO 2 ), the ears were harvested, formalin fixed and paraffin embedded, followed by immunohistochemical evaluation for donor-derived vascular network formation.
Isolation of Porcine Islets
Porcine pancreata were obtained from market weight gilts (Landrace X Yorkshire, 6
months old, weighing 100-110 kg). ice-cold HBSS containing 20% FBS when greater than 50% of the islets were released from the acinar tissue. Islets were purified using an iodixanol density gradient as previously described 4 .
Fabrication of artificial tissues carrying adipocytes and islets
Cord blood EPCs and ASCs combined at a ratio of 4:1 (8x10 5 EPCs : 2x10 5 ASCs) in a final volume of 21 µl were additionally mixed with 129 µl freshly isolated human adipocytes (packed cell volume) or 150 freshly isolated porcine islets (150 µl) followed by combination with 350 µl rat-tail collagen/fibronectin gel. The cell suspensions were polymerized in a 24-well dish (0.5 ml/well) for 30 minutes at 37 o C, then covered with 1 ml EBM-2/10%FBS (for gels carrying adipocytes) or 1:1 EGM-2:CMRL 1066 (Mediatech, Manassas, VA) with 10%FBS (for gels carrying islets). The following day gels were implanted subcutaneously as described above for 14 days.
Evaluation of VEGF accumulation in ASC conditioned media
ASCs (passage 1) were plated in the wells of 24 well plate in density 50,000 cells/cm 2 in EBM-2/5%FBS. Next day media on the wells were exchange to 0. 
